INTELLIA THERAPEUTICS, INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 20.76 USD | +3.70% |
|
-3.76% | -31.91% |
| Apr. 15 | Intellia Therapeutics, Inc. Appoints Michael P. Dube as Principal Accounting Officer | CI |
| Mar. 25 | Intellia Therapeutics Ends Development Agreement With Regeneron Pharmaceuticals | MT |
Valuation
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Capitalization 1 | 717.1 | 3,514 | 8,799 | 2,974 | 2,731 | 2,002 | - | - |
| Enterprise Value (EV) 1 | 659.9 | 2,917 | 7,713 | 1,712 | 1,718 | 1,285 | 1,011 | 914.9 |
| P/E ratio | -6.95 x | -22.7 x | -31.3 x | -5.66 x | -5.63 x | -3.75 x | -3.92 x | -3.77 x |
| Yield | - | - | - | - | - | - | - | - |
| Capitalization / Revenue | 16.6 x | 60.6 x | 266 x | 57.1 x | 75.3 x | 39.8 x | 38.2 x | 16.7 x |
| EV / Revenue | 15.3 x | 50.3 x | 233 x | 32.8 x | 47.4 x | 25.6 x | 19.3 x | 7.63 x |
| EV / EBITDA | -6.55 x | -22.4 x | -29.6 x | -3.8 x | -3.39 x | -2.53 x | -2.02 x | -2.06 x |
| EV / FCF | -5.99 x | -54.5 x | -32.4 x | -4.94 x | -4.21 x | -3.38 x | -2.64 x | -2.7 x |
| FCF Yield | -16.7% | -1.83% | -3.08% | -20.3% | -23.7% | -29.6% | -37.9% | -37.1% |
| Price to Book | 2.73 x | 5.78 x | 8.06 x | 2.46 x | 2.7 x | 2.5 x | 2.6 x | 2.84 x |
| Nbr of stocks (in thousands) | 48,882 | 64,594 | 74,419 | 85,234 | 89,555 | 96,439 | - | - |
| Reference price 2 | 14.67 | 54.40 | 118.2 | 34.89 | 30.49 | 20.76 | 20.76 | 20.76 |
| Announcement Date | 2/27/20 | 2/25/21 | 2/24/22 | 2/23/23 | 2/22/24 | - | - | - |
1USD in Million2USD
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Net sales 1 | 43.1 | 57.99 | 33.05 | 52.12 | 36.28 | 50.25 | 52.42 | 119.9 |
| EBITDA 1 | -100.8 | -130.3 | -261 | -450.6 | -506.3 | -508.5 | -501.1 | -443.7 |
| EBIT 1 | -106.4 | -136.6 | -267.8 | -458.2 | -515.3 | -529 | -554.8 | -578.3 |
| Operating Margin | -246.78% | -235.51% | -810.37% | -879.04% | -1,420.51% | -1,052.83% | -1,058.45% | -482.18% |
| Earnings before Tax (EBT) 1 | -99.53 | -134.2 | -267.9 | -474.2 | -481.2 | -522.6 | -523.8 | -561.2 |
| Net income 1 | -99.53 | -134.2 | -267.9 | -474.2 | -481.2 | -511.8 | -523.4 | -557.9 |
| Net margin | -230.92% | -231.46% | -810.49% | -909.78% | -1,326.51% | -1,018.46% | -998.55% | -465.15% |
| EPS 2 | -2.110 | -2.400 | -3.780 | -6.160 | -5.420 | -5.531 | -5.302 | -5.512 |
| Free Cash Flow 1 | -110.2 | -53.5 | -237.8 | -346.8 | -408.1 | -379.9 | -382.8 | -339.4 |
| FCF margin | -255.7% | -92.25% | -719.41% | -665.46% | -1,124.94% | -756.06% | -730.25% | -282.96% |
| FCF Conversion (EBITDA) | - | - | - | - | - | - | - | - |
| FCF Conversion (Net income) | - | - | - | - | - | - | - | - |
| Dividend per Share 2 | - | - | - | - | - | - | - | - |
| Announcement Date | 2/27/20 | 2/25/21 | 2/24/22 | 2/23/23 | 2/22/24 | - | - | - |
1USD in Million2USD
Estimates
Income Statement Evolution (Quarterly data)
| Fiscal Period: December | 2021 Q3 | 2021 Q4 | 2022 Q1 | 2022 Q2 | 2022 Q3 | 2022 Q4 | 2023 Q1 | 2023 Q2 | 2023 Q3 | 2023 Q4 | 2024 Q1 | 2024 Q2 | 2024 Q3 | 2024 Q4 | 2025 Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net sales 1 | 7.204 | 12.58 | 11.25 | 14.03 | 13.27 | 13.57 | 12.61 | 13.59 | 11.99 | -1.917 | 9.065 | 19.13 | 9.758 | 9.531 | 17.66 |
| EBITDA | - | - | - | - | -103.6 | -108.1 | - | - | - | - | - | - | - | - | - |
| EBIT 1 | -71.99 | -80.42 | -144.2 | -98.3 | -105.5 | -110.1 | -112 | -132.3 | -131.1 | -139.9 | -134.8 | -129.3 | -139.8 | -144 | -145.3 |
| Operating Margin | -999.35% | -639.03% | -1,281.96% | -700.65% | -795.49% | -811.07% | -888.13% | -973.47% | -1,093.29% | 7,297.44% | -1,486.57% | -675.83% | -1,432.27% | -1,510.45% | -822.5% |
| Earnings before Tax (EBT) 1 | -71.64 | -81.24 | -146.9 | -100.7 | -113.2 | -113.4 | -103.1 | -123.7 | -122.2 | -132.2 | -127.2 | -123.9 | -133.1 | -138.2 | -140.2 |
| Net income 1 | -71.64 | -81.24 | -146.9 | -100.7 | -113.2 | -113.4 | -103.1 | -123.7 | -122.2 | -132.2 | -125.3 | -121.4 | -130.9 | -135.8 | -140.2 |
| Net margin | -994.5% | -645.56% | -1,305.3% | -717.59% | -853.53% | -835.53% | -818.07% | -909.82% | -1,019.21% | 6,894.16% | -1,381.96% | -634.75% | -1,341.55% | -1,425.23% | -793.79% |
| EPS 2 | -0.9700 | -1.090 | -1.960 | -1.330 | -1.490 | -1.380 | -1.170 | -1.400 | -1.380 | -1.460 | -1.371 | -1.265 | -1.402 | -1.425 | -1.406 |
| Dividend per Share | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Announcement Date | 11/4/21 | 2/24/22 | 5/5/22 | 8/4/22 | 11/3/22 | 2/23/23 | 5/4/23 | 8/3/23 | 11/9/23 | 2/22/24 | - | - | - | - | - |
1USD in Million2USD
Estimates
Balance Sheet Analysis
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Net Debt 1 | - | - | - | - | - | - | - | - |
| Net Cash position 1 | 57.2 | 597 | 1,086 | 1,262 | 1,012 | 717 | 991 | 1,087 |
| Leverage (Debt/EBITDA) | - | - | - | - | - | - | - | - |
| Free Cash Flow 1 | -110 | -53.5 | -238 | -347 | -408 | -380 | -383 | -339 |
| ROE (net income / shareholders' equity) | -36.3% | -33.7% | - | -41.7% | -42.1% | -61% | -70.8% | -56.3% |
| ROA (Net income/ Total Assets) | - | - | - | -33.7% | -34.1% | -47.4% | -39% | -77.7% |
| Assets 1 | - | - | - | 1,407 | 1,411 | 1,080 | 1,344 | 718 |
| Book Value Per Share 2 | 5.380 | 9.410 | 14.70 | 14.20 | 11.30 | 8.320 | 8.000 | 7.310 |
| Cash Flow per Share 2 | - | -0.8900 | - | -4.330 | -4.440 | -4.740 | -3.000 | -3.360 |
| Capex 1 | 6.79 | 3.59 | 12.8 | 13.6 | 14 | 13.3 | 11.8 | 11.1 |
| Capex / Sales | 15.76% | 6.18% | 38.59% | 26.01% | 38.55% | 26.52% | 22.48% | 9.25% |
| Announcement Date | 2/27/20 | 2/25/21 | 2/24/22 | 2/23/23 | 2/22/24 | - | - | - |
1USD in Million2USD
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Year-on-year evolution of the Yield
Change in Enterprise Value/EBITDA
Trading Rating
Investor Rating
ESG Refinitiv
B-
Sell
Buy
Mean consensus
BUY
Number of Analysts
28
Last Close Price
20.76
USD
Average target price
71.16
USD
Spread / Average Target
+242.77%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -31.91% | 2B | |
| +1.51% | 42.75B | |
| +8.57% | 41.34B | |
| +49.22% | 41.61B | |
| -12.36% | 26.59B | |
| +8.92% | 25.49B | |
| -25.13% | 18.12B | |
| +29.17% | 12.24B | |
| -3.12% | 11.76B | |
| +6.35% | 11B |
- Stock Market
- Equities
- NTLA Stock
- Financials Intellia Therapeutics, Inc.
